Overview

Study for Patients Previously Treated in Avapritinib Clinical Trials

Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension study to provide long term safety data for GIST patients who are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical trials.
Phase:
Phase 4
Details
Lead Sponsor:
Blueprint Medicines Corporation